By Editorial TeamThe trajectory of artificial intelligence in healthcare is undeniably steep, yet within the burgeoning cardiac AI sub-market, a significant divergence in growth projections presents a critical analytical challenge for investors and industry observers. While consensus points to a substantial expansion from an estimated $1.7-2.2 billion in 2025, and an estimated $2.1-2.8 billion in 2026, the long-term outlook for 2033 ranges wildly from $14.8 billion to an ambitious $36.8 billion (by 2035). This wide analytical disagreement underscores the complexity of valuing an ecosystem rapidly evolving across diverse modalities, from imaging-centric solutions to more distributed monitoring platforms. Understanding where growth will materialize, and which business models offer the most durable funding trajectories, is paramount for venture capital firms and growth equity investors eyeing this space.
Deconstructing the Cardiac AI Market: Imaging vs. Monitoring
The cardiac AI market is not monolithic; it segments into distinct areas such as ECG-AI, echo-AI, CT-AI, and monitoring-AI. Historically, significant venture capital funding in healthcare AI has flowed into imaging-AI, driven by the promise of enhanced diagnostic accuracy and efficiency. Companies like HeartFlow, which leverages AI to create 3D models of coronary arteries from CT scans to assess blood flow (CT-FFR), exemplify this trend. HeartFlow reported Q1 2026 revenue of $52.6 million, with full-year 2026 revenue guidance of $228 million to $232 million. Aetna now covers HeartFlow Plaque Analysis nationwide. However, the company is currently under a Civil Investigative Demand from the DOJ and facing patent litigation. HeartFlow has built a substantial patent thicket around its technology, creating a competitive barrier that new entrants often face in the form of licensing costs or litigation risk.
However, the landscape is subtly shifting. While imaging-AI continues to attract investment, the monitoring-AI segment is gaining increasing investor attention, particularly as a lower-capital alternative. This shift is driven by several factors, including the scalability of remote patient monitoring and the potential for earlier intervention in chronic cardiac conditions. This segment often involves Software as a Medical Device (SaMD) solutions that can operate independently of specialized hardware, reducing deployment costs and accelerating market penetration.
The Durability of Funding: Clinical Outcomes and Payer Contracts
Our ongoing analysis of healthcare AI funding activity, encompassing round sizes, investor rosters, valuation milestones, and funding durability, consistently demonstrates a clear pattern: companies with published clinical outcomes and established payer contracts exhibit more durable funding trajectories. This holds true across all segments of cardiac AI. For instance, companies like iRhythm, a peer to Hello Heart in the cardiac monitoring space, have built a significant data moat through millions of labeled ECG recordings. iRhythm reported Q1 2026 revenue of $199.4 million and increased its fiscal year 2026 revenue guidance to $875 million to $885 million. The company has faced a warning letter from the FDA regarding its Zio AT device and is currently subject to a limited-scope US Department of Justice Civil Investigative Demand concerning its 2023 mobile cardiac telemetry services. This proprietary dataset makes it nearly impossible for a new entrant to match their diagnostic accuracy without substantial time and investment, directly contributing to their funding durability and market leadership. The ability to demonstrate real-world evidence (RWE) of improved patient outcomes and cost savings is a crucial differentiator for securing both payer contracts and subsequent funding rounds.
AliveCor, another prominent player in the cardiac monitoring space, similarly benefits from demonstrating clinical utility and securing regulatory clearances. AliveCor received FDA clearance in January 2026 for new cardiac determinations for its Kardia 12L ECG System, bringing the total to 39 cleared determinations. CMS approved Medicare payment for Kardia 12L in hospital outpatient settings in 2025. However, in March 2025, the U.S. Court of Appeals ruled in favor of Apple, invalidating AliveCor’s patents for monitoring heart rates. Their focus on accessible, at-home ECG monitoring aligns with the broader trend toward decentralized healthcare, offering solutions that can be integrated into remote patient monitoring (RPM) programs. The establishment of clear CPT codes (Category I & III) for these services is a critical factor for investor confidence, as it provides a defined reimbursement pathway, de-risking the commercialization process.
Monitoring-AI as a Lower-Capital Entry Point: The Hello Heart Case
Within the monitoring-AI sub-segment, companies like Hello Heart are demonstrating the potential for growth through a focus on behavioral and remote patient monitoring, particularly for conditions like hypertension and heart disease. Hello Heart raised $70 million in Series D financing in May 2022. Its flagship solution is an FDA-cleared blood pressure monitor coupled with an app. As a peer to iRhythm, Hello Heart’s approach often involves engaging patients directly through digital platforms, offering personalized insights and coaching. This model, while distinct from the diagnostic-heavy imaging AI, presents a lower-capital-intensive path to market entry compared to the substantial R&D and regulatory hurdles associated with developing complex imaging algorithms and securing 510(k) clearance or De Novo classification for novel diagnostic tools. FDA guidance on digital health technologies
The attractiveness of this lower-capital model for investors lies in its potential for faster scaling and a quicker path to revenue generation, especially when coupled with strong engagement metrics and evidence of clinical impact. While imaging-AI companies like HeartFlow require extensive clinical trials and regulatory approvals for their SaMD solutions, monitoring-AI often leverages existing device clearances or focuses on wellness and behavioral interventions that may have different, though still rigorous, evidentiary requirements. The emphasis on user engagement and adherence in the monitoring space can also translate into more predictable recurring revenue streams, a highly valued characteristic for growth equity firms.
Navigating Analyst Disagreement and Investment Strategy
The wide analyst disagreement on the 2033 market size for cardiac AI, ranging from $14.8 billion to $36.8 billion, highlights the inherent uncertainty and diverse assumptions underlying these projections. Factors contributing to this variance include differing views on the speed of regulatory adoption, the pace of payer reimbursement expansion, and the penetration rate of AI into various clinical workflows. For VCs and growth equity investors, this disparity underscores the necessity of granular due diligence. Understanding a company’s pathway to regulatory approval (e.g., 510(k) clearance, De Novo classification, or Breakthrough Device Designation), its strategy for securing CPT codes, and its ability to generate robust real-world evidence are critical. AMA CPT code application process
Furthermore, the ability to demonstrate compliance with standards like HIPAA, HITRUST, or SOC 2 Type II is non-negotiable for any cardiac AI startup handling sensitive patient data. A clean data room during due diligence, showcasing organized FDA correspondence, security reports, and customer contracts, signals a mature and well-managed company, which is a significant de-risking factor for investors. HITRUST CSF framework details
The cardiac AI market is poised for significant growth, but the distribution of that growth across sub-segments will be uneven. While imaging-AI, exemplified by companies like HeartFlow, continues to command attention for its diagnostic prowess, the monitoring-AI segment, with players such as iRhythm, AliveCor, and Hello Heart, offers a compelling, often lower-capital, pathway to market. Investment strategies that prioritize companies with clear clinical validation, established payer contracts, and robust data security protocols are best positioned to capitalize on this evolving landscape, irrespective of the precise upper bound of the 2033 market projection.
Frequently Asked Questions
What is the projected growth for the cardiac AI market, and what is causing the wide range in these projections?
The cardiac AI market is projected to grow from an estimated $1.7-2.2 billion in 2025 to a wide range of $14.8 billion to $36.8 billion by 2033-2035. This significant divergence is due to the market’s rapid evolution across diverse modalities like imaging-centric solutions and monitoring platforms, making it challenging to value the long-term outlook.
What are the key differences between the imaging-AI and monitoring-AI segments within the cardiac AI market?
Imaging-AI, exemplified by companies like HeartFlow, focuses on enhanced diagnostic accuracy through technologies like 3D models from CT scans, often requiring substantial venture capital. Monitoring-AI, like iRhythm and AliveCor, is gaining attention as a lower-capital alternative, focusing on remote patient monitoring and earlier intervention, often using Software as a Medical Device (SaMD) solutions.
What factors contribute to the ‘durable funding trajectories’ for cardiac AI companies?
Companies with published clinical outcomes and established payer contracts demonstrate more durable funding trajectories. This is often supported by significant data moats, like iRhythm’s labeled ECG recordings, and the ability to demonstrate real-world evidence of improved patient outcomes and cost savings, which helps secure payer contracts and subsequent funding rounds.
How does the monitoring-AI segment offer a lower-capital entry point compared to imaging-AI?
Monitoring-AI, as seen with Hello Heart, often involves engaging patients directly through digital platforms and offers personalized insights, frequently using FDA-cleared blood pressure monitors coupled with apps. This model presents a lower-capital-intensive path to market entry compared to the substantial R&D and regulatory hurdles associated with developing complex imaging algorithms and securing extensive clearances for novel diagnostic tools.
